secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001356576-23-000070
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q3 GAAP net loss $16M; raises FY adjusted op earnings guide to $95-110M
--------------------------------------------------------------------------------

- Total revenues $153.9M; Qelbree net sales $37.1M (+103% YoY), GOCOVRI $32.9M (+18% YoY).
- GAAP net loss of $16.0M ($0.29 diluted EPS); adjusted operating earnings $37.3M, up 47% YoY.
- FY 2023 adjusted operating earnings guidance raised to $95-110M from $75-100M; total revenue guidance $590-610M.
- FDA accepted SPN-830 NDA resubmission for Parkinson's; PDUFA date April 5, 2024.
- Qelbree IQVIA prescriptions 163,344 (+73% YoY); prescriber base expanded to ~24,189.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000070/0001356576-23-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000070/supn-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001356576-23-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer